Dr. Jameel Muzaffar is an Assistant Member in the Moffitt Cancer Center Department of Head and Neck-Endocrine Oncology. Dr. Muzaffar received his MBBS degree from Maulana Azad Medical College in India. He completed an Internal Medicine Residency at St. Mary’s Health Service in St. Louis, MO. Dr. Muzaffar was employed at the Myeloma Institute of Research and Therapy at the University of Arkansas for Medical Sciences at the rank of Assistant Professor. He also served as the Physician Director of Infusion 4, Winthrop Rockefeller Cancer Institute. Dr. Muzaffar was previously employed at Moffitt Cancer Center in the Department of Internal Medicine/Internal & Hospital Medicine Program. He recently completed a Clinical Fellowship in Hematology-Oncology at the University of Florida, Gainesville. Dr. Muzaffar’s clinical interest includes taking care of patients with advanced stage head and neck cancers and endocrine cancers. His clinical focus is developing a multi-disciplinary care approach involving radiation oncology, surgery, medical oncology, nutrition, speech pathology, pharmacy, palliative care, and social work to provide comprehensive care to head and neck cancer and thyroid cancer patients. His research interest is in developing new therapy options for patients with advanced stage cancers and to bring innovative trials for the benefit of these patients.
Education & Training
University of Florida at Gainesville - Hematology Oncology
CLINICAL TRIAL 20274
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Condition: Head & Neck
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Radiotherapy (); cisplatin ()
CLINICAL TRIAL 20132
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
Intervention: FLX475 (); Pembrolizumab (Keytruda)
CLINICAL TRIAL 20315
Phase II Study of XL184 (cabozantinib) in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after One Prior VEGFR-Targeted Therapy
Condition: Head & Neck
Intervention: BMS-936558 (Nivolumab); Cabozantinib (XL 184); Ipilimumab (); Nivolumab (Opdivo); Yervoy (Ipilimumab)
CLINICAL TRIAL 20306
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects with Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
Condition: Head & Neck
Intervention: Rivoceranib ()
Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, Masannat J, Song F, Hernandez-Prera JC, Wenig BM, Molina H, Farinhas JM, McMullen CP, Wadsworth JT, Patel KB, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers (Basel). 2021 Mar.13(5). Pubmedid: 33803335. Pmcid: PMC7967147.
Muzaffar J, Bari S, Kirtane K, Chung CH. Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2021 Jan.13(2). Pubmedid: 33477635. Pmcid: PMC7831487.
Abou-Foul AK, Muzaffar J, Diakos E, Best JE, Momtahan N, Jayaram S. Correlation Between Thyroid Fine Needle Aspiration Cytology and Postoperative Histology: A 10-Year Single-Centre Experience. Cureus. 2021 Apr.13(4):e14504. Pubmedid: 34007757. Pmcid: PMC8123937.
Bari S, Muzaffar J, Chan A, Jain SR, Haider AM, Adams Curry M, Hostler CJ. Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. J Oncol. 2019 Jan.2019:2989048. Pubmedid: 31275380. Pmcid: PMC6582789.
Khan AM, Muzaffar J, Murthy H, Wingard JR, Moreb JS. Corrigendum to "Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features". Case Rep Hematol. 2019 Aug.2019:1548610. Pubmedid: 31467738. Pmcid: PMC6701371.
Bari S, Muzaffar J, Chan A, Jain SR, Haider AM, Adams Curry M, Hostler CJ. Corrigendum to "Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer". J Oncol. 2019 Aug.2019:7921582. Pubmedid: 31531021. Pmcid: PMC6719266.
Nguyen TC, Bajwa R, Bari S, Ali A, Paul Skelton W, Federico RA, Bishnoi R, Wray JW, Zlotecki RA, Dang LH, Muzaffar J. Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer. Oxf Med Case Reports. 2018 Jan.2018(1):omx078. Pubmedid: 29340160. Pmcid: PMC5761507.
Khan AM, Muzaffar J, Murthy H, Wingard JR, Moreb JS. Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features. Case Rep Hematol. 2018 Feb.2018:9052314. Pubmedid: 29785311. Pmcid: PMC5896379.
Best J, Muzaffar J, Mitchell-Innes A. Quality of information available via the internet for patients with head and neck cancer: are we improving?. Eur Arch Otorhinolaryngol. 2015 Nov.272(11):3499-3505. Pubmedid: 25370600.
Hardman J, Muzaffar J, Nankivell P, Coulson C. Tympanoplasty for Chronic Tympanic Membrane Perforation in Children: Systematic Review and Meta-analysis. Otol Neurotol. 2015 Jun.36(5):796-804. Pubmedid: 25899552.
Abdallah AO, Atrash S, Shahid Z, Jameel M, Grazziutti M, Apewokin S, Kumar NS, Restrepo A, Waheed S, Van Rhee F, Heuck CJ, Johann D, Barlogie B, Usmani SZ. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Jun.14(3):211-214. Pubmedid: 24373936.
Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013 Jun.121(23):4753-4757. Pubmedid: 23603914. Pmcid: PMC3674673.
Muzaffar J, Katragadda L, Haider S, Abdallah AO, Anaissie E, Usmani SZ. Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant. Acta Haematol. 2013 Dec.130(3):146-149. Pubmedid: 23689541.
Abdallah AO, Atrash S, Muzaffar J, Abdallah M, Kumar M, Van Rhee F, Barlogie B. Successful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2013 Aug.13(4):502-506. Pubmedid: 23747080.
Katragadda L, Shahid Z, Restrepo A, Muzaffar J, Alapat D, Anaissie E. Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease. Transpl Infect Dis. 2013 Aug.15(4):354-360. Pubmedid: 23578205.
Abdallah AO, Westfall C, Brown H, Muzaffar J, Atrash S, Nair B. Unilateral conjunctival AL kappa amyloidosis with trace evidence of systemic amyloidosis. Am J Case Rep. 2013 Apr.13:102-105. Pubmedid: 23569501. Pmcid: PMC3615912.
Muzaffar J, Usmani S, Abdallah AO, Anaissie E, Cottler-Fox M, Restrepo A. High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma in HIV-positive patients in the highly active antiretroviral therapy era: the myeloma institute of research and therapy experience. Clin Lymphoma Myeloma Leuk. 2013 Apr.13(2):171-174. Pubmedid: 23313066.
Muzaffar J, Katragadda L, Haider S, Javed A, Anaissie E, Usmani S. Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature. Int J Hematol. 2012 Jan.95(1):102-106. Pubmedid: 22170228.
Pillai U, Muzaffar J, Uppaluri C. Peripheral arterial thrombosis with presence of anti-centromere antibodies and polycythemia vera. Mo Med. 2009 Sep.106(5):369-372. Pubmedid: 19902720.
Pillai U, Muzaffar J, Sen S, Yancey A. Grapefruit juice and verapamil: a toxic cocktail. South Med J. 2009 Mar.102(3):308-309. Pubmedid: 19204629.
Singh P, Singla M, Gupta N, Muzaffar J, Babu R, Sakhuja P, Aggarwal A, Kar P. Inflammatory pseudotumour of the liver: a diagnostic dilemma. Trop Gastroenterol. 2008 Jan.29(1):40-43. Pubmedid: 18564668.
Muzaffar J, Venkata Krishnan P, Gupta N, Kar P. Dengue encephalitis: why we need to identify this entity in a dengue-prone region. Singapore Med J. 2006 Nov.47(11):975-977. Pubmedid: 17075667.
Gupta N, Krishnan PV, Muzaffar J, Arora A, Anuradha S, Gondal R, Agarwal A, Kar P. Cystic ductal adenocarcinoma of pancreas: an unusual variant. Trop Gastroenterol. 2006 Jul.27(3):131-133. Pubmedid: 17310557.
Muzaffar J, Madan K, Sharma MP, Kar P. Randomized, single-blind, placebo-controlled multicenter trial to compare the efficacy and safety of metronidazole and satranidazole in patients with amebic liver abscess. Digest Dis Sci. 2006 Dec.51(12):2270-2273. Pubmedid: 17103040.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub